In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
- Preliminary exploratory efficacy results from phase 1 study show an overall response rate of 58.8 percent with single agent DS-3201, an investigational and potential first-in-class EZH1/2 dual inhibitor, in patients with relapsed or refractory non-Hodgkin lymphomas
- Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN data
- Clinical results suggest that ibrutinib inhibits B cells and follicular helper T cells believed to play a critical role in treating chronic graft-versus-host disease (cGVHD), while preserving immune memory and Th1 T cells
Video Contest Winner Gets $2,000, Works With Emmy-Winning Director To Create TV Ad That Debuts at Atlanta International Auto Show Before Airing Nationwide
- Follow-up data from RESONATE™-2 suggest long-term benefits of ibrutinib as a first-line therapy in CLL, via the longest patient-reported outcomes to date and a progression-free survival rate of 85 percent